Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Study of Teriparatide (FORTEO) to Treat Adults With Osteogenesis Imperfecta (OI)

This study has been completed.
Eli Lilly and Company
Osteogenesis Imperfecta Foundation
National Institutes of Health (NIH)
National Center for Research Resources (NCRR)
Information provided by (Responsible Party):
Eric Orwoll, MD, Oregon Health and Science University Identifier:
First received: August 16, 2005
Last updated: October 30, 2013
Last verified: October 2013
No Study Results Posted on for this Study
  Study Status: This study has been completed.
  Study Completion Date: January 2011
  Primary Completion Date: January 2011 (Final data collection date for primary outcome measure)
Publications automatically indexed to this study by Identifier (NCT Number):